120 related articles for article (PubMed ID: 8894076)
1. Effect of the cholecystokinin-B receptor antagonist L-365,260 on lactate-induced panic attacks in panic disorder patients.
van Megen HJ; Westenberg HG; den Boer JA
Biol Psychiatry; 1996 Oct; 40(8):804-6. PubMed ID: 8894076
[No Abstract] [Full Text] [Related]
2. A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder.
Kramer MS; Cutler NR; Ballenger JC; Patterson WM; Mendels J; Chenault A; Shrivastava R; Matzura-Wolfe D; Lines C; Reines S
Biol Psychiatry; 1995 Apr; 37(7):462-6. PubMed ID: 7786960
[TBL] [Abstract][Full Text] [Related]
3. Effect of CI-988, a cholecystokinin-B receptor antagonist, on lactate-induced panic.
Cowley DS; Adams JB; Pyke RE; Cook J; Zaccharias P; Wingerson D; Roy-Byrne PP
Biol Psychiatry; 1996 Sep; 40(6):550-2. PubMed ID: 8879478
[No Abstract] [Full Text] [Related]
4. Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients.
Pols H; Verburg K; Hauzer R; Meijer J; Griez E
Biol Psychiatry; 1996 Nov; 40(9):913-7. PubMed ID: 8896779
[TBL] [Abstract][Full Text] [Related]
5. Cardio-respiratory and other symptom clusters in panic disorder.
Bandelow B; Amering M; Benkert O; Marks I; Nardi AE; Osterheider M; Tannock C; Tremper J; Versiani M
Anxiety; 1996; 2(2):99-101. PubMed ID: 9160609
[No Abstract] [Full Text] [Related]
6. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder.
Bradwejn J; Koszycki D; Couëtoux du Tertre A; van Megen H; den Boer J; Westenberg H
Arch Gen Psychiatry; 1994 Jun; 51(6):486-93. PubMed ID: 8192551
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of a CCKB antagonist in patients with panic disorder: preliminary findings.
Sramek JJ; Kramer MS; Reines SA; Cutler NR
Anxiety; 1994-1995; 1(3):141-3. PubMed ID: 9160564
[TBL] [Abstract][Full Text] [Related]
8. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder.
Benjamin J; Levine J; Fux M; Aviv A; Levy D; Belmaker RH
Am J Psychiatry; 1995 Jul; 152(7):1084-6. PubMed ID: 7793450
[TBL] [Abstract][Full Text] [Related]
9. Role of cholecystokinin type B receptors in ultrasound induced behavior in rats.
Voits M; Beckett SR; Marsden CA; Fink H
Peptides; 1999; 20(3):383-6. PubMed ID: 10447098
[TBL] [Abstract][Full Text] [Related]
10. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
[TBL] [Abstract][Full Text] [Related]
11. Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses.
Abelson JL; Nesse RM
Biol Psychiatry; 1994 Jul; 36(2):73-83. PubMed ID: 7948449
[TBL] [Abstract][Full Text] [Related]
12. Consistencies between recalled panic and lactate-induced panic.
Goetz RR; Klein DF; Gorman JM
Anxiety; 1994; 1(1):31-6. PubMed ID: 9160544
[TBL] [Abstract][Full Text] [Related]
13. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder.
Lydiard RB; Lesser IM; Ballenger JC; Rubin RT; Laraia M; DuPont R
J Clin Psychopharmacol; 1992 Apr; 12(2):96-103. PubMed ID: 1573046
[TBL] [Abstract][Full Text] [Related]
14. Selective blockade of cholecystokinin type B receptors with L-365,260 does not impair gallbladder contraction in normal humans.
Grasing K; Freedholm D; Murphy MG; Swigar M; Russer T; Nosher J; Lin J; Frame V; Clarke L; Seibold JR
Am J Gastroenterol; 1996 Mar; 91(3):569-73. PubMed ID: 8633511
[TBL] [Abstract][Full Text] [Related]
15. Ondansetron in the treatment of panic disorder.
Schneier FR; Garfinkel R; Kennedy B; Campeas R; Fallon B; Marshall R; O'Donnell L; Hogan T; Liebowitz MR
Anxiety; 1996; 2(4):199-202. PubMed ID: 9160623
[No Abstract] [Full Text] [Related]
16. Pentagastrin infusions in patients with panic disorder. II. Neuroendocrinology.
Abelson JL; Nesse RM; Vinik AI
Biol Psychiatry; 1994 Jul; 36(2):84-96. PubMed ID: 7524696
[TBL] [Abstract][Full Text] [Related]
17. [Role of cholecystokinin receptor in methamphetamine-induced reverse tolerance].
Shimazoe T; Fukumoto T; Shuto T; Watanabe S
Nihon Shinkei Seishin Yakurigaku Zasshi; 2002 Oct; 22(5):207. PubMed ID: 12451697
[No Abstract] [Full Text] [Related]
18. Coping behavior in patients with panic disorder.
Yamada K; Fujii I; Akiyoshi J; Nagayama H
Psychiatry Clin Neurosci; 2004 Apr; 58(2):173-8. PubMed ID: 15009823
[TBL] [Abstract][Full Text] [Related]
19. Cholecystokinin and panic disorder: past and future clinical research strategies.
Bradwejn J; Koszycki D
Scand J Clin Lab Invest Suppl; 2001; 234():19-27. PubMed ID: 11713976
[TBL] [Abstract][Full Text] [Related]
20. A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients.
Ravaris CL; Friedman MJ; Hauri PJ; McHugo GJ
J Clin Psychopharmacol; 1991 Dec; 11(6):344-50. PubMed ID: 1770152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
